Sanofi : Starting a new chapter
>Selling its stake in Regeneron - Sanofi is pressing ahead with its major moves, which we clearly welcome. After the announcement to operate its OTC franchise on a standalone basis and the spin-off of its API company in 2022, the group yesterday announced it was selling its stake in Regeneron. We are not surprised by this strategic decision which very much ties in with the group’s story. The recent rearrangements made to the agreements between the two parties and Sano...Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.